Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of freeze-dried human diploid cell rabies vaccine with different post-exposure regimens
ChiCTR2600119349Phase 3Not yet recruiting
- Sponsor
- Hubei Provincial Center for Disease Control and Prevention
- Start
- Feb 2026
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of human rabies vaccine in rabies (5 arms), sponsored by Hubei Provincial Center for Disease Control and Prevention. Primary endpoints: Seroconversion rate and GMC of serum neutralizing antibodies 14 days after first dose in all pre-vaccination negative subjects (test groups), Seroconversion rate of neutralizing antibodies 14 days after last dose in all pre-vaccination negative subjects and 2 more. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
human rabies vaccine
03
Conditions
rabies
Beyond the preview
Go deeper on ChiCTR2600119349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119349.